Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (191)	10/16/2002 12:13:44 PM
From: nigel bates	Respond to of 447

I suppose it could be an unconsidered - and inaccurate - comment from the spokesperson, but given the circumstances, would the company not be careful about language ?

To: tuck who wrote (191)	10/16/2002 12:31:25 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 447

Full quote, with emphasis: This side-effect was known to AstraZeneca throughout the drug's clinical development* and was included on the original label for Iressa in Japan,* So, no surprise you don't remember anyone talking about it. On the imcl board, for the longest time, there was an intelligent comparison of side effect profiles c225 vs iressa. Diarrhea was the only specific comparator, but there were several comments on the lipid-loving qualities of iressa, explaining its preference for and apparent effect in the lungs. Any published, or widely rumored, IP side effect would have been exploited by that group of posters, so I would guess there was none...maybe just clinicians suspicions based on a few observations and, or course, the central database under lock and key and guarded by Fluffy....